Azenta Reports Steep Q2 Loss, $149M Goodwill Impairment, and Cuts Full-Year Guidance
AZTA sits 16% above its 52-week low of $19.87 on elevated volume (1.9× avg).
Summary
Azenta, Inc. reported a significantly wider Q2 operating loss of $165.8 million, including a $149 million goodwill impairment charge, and substantially lowered its full-year fiscal 2026 revenue and Adjusted EBITDA margin guidance.
Key Events · Earnings and Guidance · AZTA
-
Steep Q2 Operating Loss
Reported a GAAP operating loss of $165.8 million for Q2 FY2026, a significant increase from $18.2 million in the prior year, driven by execution gaps and a cautious demand environment.
-
$149 Million Goodwill Impairment
Recognized a substantial non-cash goodwill impairment charge of $149 million, primarily affecting the Multiomics and Sample Management Solutions reporting units, indicating a re-evaluation of asset values.
-
Substantial Full-Year Guidance Cut
Lowered fiscal 2026 revenue guidance to $603-$621 million (from prior 3-5% growth) and adjusted EBITDA margin expectations, reflecting reduced organic growth and profitability.
-
Long-Range Plan Extended
The timeline for achieving long-range plan targets has been extended by one year, from 2028 to 2029, in connection with the revised 2026 outlook.
Analysis · AZTA · Technology
The Q2 FY2026 results for Azenta, Inc. are highly concerning, marked by a dramatic increase in operating loss to $165.8 million, primarily due to a $149 million non-cash goodwill impairment charge. This impairment suggests a significant re-evaluation of the value of acquired assets, particularly in the Multiomics and Sample Management Solutions segments, indicating underperformance relative to prior expectations. The company also significantly lowered its full-year fiscal 2026 guidance for both revenue and Adjusted EBITDA margin, signaling a deteriorating demand environment and execution challenges. Furthermore, the extension of the long-range plan timeline by a year underscores a slower path to achieving strategic targets. The failure to close the B Medical Systems divestiture due to the buyer's financing issues adds further uncertainty and risk. These combined factors present a very negative outlook for Azenta, impacting investor confidence and suggesting continued operational headwinds.
At the time of this filing, AZTA was trading at $23.00 on NASDAQ in the Technology sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $19.87 to $41.73. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.